PlainRecalls
FDA Drug Critical Class I Terminated

Atovaquone Oral Suspension USP, 750 mg per 5 mL sachets, 20 Units x 5 mL cartons, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478, NDC 50268-086-12.

Reported: April 24, 2024 Initiated: March 28, 2024 #D-0444-2024

Product Description

Atovaquone Oral Suspension USP, 750 mg per 5 mL sachets, 20 Units x 5 mL cartons, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478, NDC 50268-086-12.

Reason for Recall

Microbial contamination of a non-sterile product: potential Bacillus cereus contamination.

Details

Recalling Firm
AvKARE
Units Affected
153 cartons
Distribution
US Nationwide.
Location
Pulaski, TN

Frequently Asked Questions

What product was recalled?
Atovaquone Oral Suspension USP, 750 mg per 5 mL sachets, 20 Units x 5 mL cartons, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478, NDC 50268-086-12.. Recalled by AvKARE. Units affected: 153 cartons.
Why was this product recalled?
Microbial contamination of a non-sterile product: potential Bacillus cereus contamination.
Which agency issued this recall?
This recall was issued by the FDA Drug on April 24, 2024. Severity: Critical. Recall number: D-0444-2024.